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ABSTRACT 
Glaucoma is a chronic optic nerve disease in which the primary damage occurs to the retinal 
ganglion cell axons. Therapies that prevent the death of retinal ganglion cells should be 
theoretically beneficial. Despite promising preclinical studies, however, almost all clinical studies 
with pharmacological approaches for neuroprotection in neurologic and eye diseases, including 
glaucoma, have so far failed to show efficacy. As the evidence supporting the neuroprotective 
efficacy of a ketogenic diet (KD) in a number of neurodegenerative diseases continues to grow, it is 
conceivable that this metabolic approach might be useful in chronic glaucoma. Putative cellular 
mechanisms underlying the neuroprotective activity of the KD have been identified in 
neurological studies, including effects on energy metabolism, the GABA system, glutamate-
mediated toxicity, antioxidant mechanisms, programmed cell death, anti-inflammatory 
mechanisms, and the production of kynurenic acid. Of note, the same mechanisms are thought to 
be involved in glaucoma. Given these mechanistic similarities, testing the KD for its efficacy in 
neurodegenerative diseases of the eye is proposed. 
KEY WORDS 
Glaucoma, ketogenic diet, optic nerve diseases, neuroprotection, mitochondrial disease 
©2012, Medical Hypothesis, Discovery & Innovation (MEHDI) Ophthalmology Journal.  
All rights reserved.   
 
Correspondence to: 
Prof. Tomasz Zarnowski, Chair of Ophthalmology, Medical University, Lublin, Poland, Tel: +48815324827, E-mail: zarnowskit@poczta.onet.pl 
 
INTRODUCTION  
Glaucoma is the most common optic neuropathy and the 
second most common cause of blindness worldwide [1]. 
Primary open-angle glaucoma (POAG) is the most frequent type 
of glaucoma, with risk factors that include elevated intraocular 
pressure (IOP), family history, old age, or black racial ancestry 
[2]. Although the primary pathogenesis of POAG remains 
unknown, chronic retinal ganglion cell apoptosis with 
consequent progressive damage to axons at the optic nerve 
head has been implicated [3]. At the cellular level and 
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consistently with neurodegenerative processes of other CNS 
disorders [4], glutamate-mediated excitotoxicity, intracellular 
calcium overload, mitochondrial dysfunction, and the 
generation of reactive oxygen species are likely to be involved 
in the POAG-induced optic nerve neuropathy [3]. 
 There is growing evidence that inborn mitochondrial 
dysfunctions may play an important role in a large proportion 
of patients affected by POAG. Results of a recent study reveal a 
spectrum of mitochondrial abnormalities in patients with 
POAG, implicating oxidative stress and suggesting that 
mitochondrial dysfunction may be a risk factor for POAG [5]. 
The development of glaucomatous damage in that 
subpopulation of patients often could not be explained by risk 
factors typically associated with POAG, such as family history, 
systemic risk factors, or high IOP. Thus, studies focusing on the 
association between mitochondrial function and glaucoma 
open a novel research approach into the pathologies and 
potential treatments of POAG-related optic neuropathies [6].  
The list of optic neuropathies already proven to be associated 
with mitochondrial abnormalities can be seen in patients with 
Leber’s hereditary optic neuropathy (LHON), or in certain 
patients with optic neuritis, multiple sclerosis, Wolfram’s 
syndrome, dominant optic atrophy, or non-arteritic ischaemic 
optic neuropathy [7,8]. In contrast to chronic POAG, retinal 
ganglion cell apoptosis and axonal injury at the optic nerve 
head in LHON is subacute [7]. Interestingly, in this mtDNA-
mediated disorder, normal tension glaucoma of an unknown 
pathomechanism appears to be present more often [9]. 
However, the exact mechanisms by which mitochondrial 
abnormalities put the optic nerve at risk remain uncertain. It is 
possible that a high concentration of mitochondria at the optic 
nerve head implies the dependency of neuronal survival on 
mitochondrial function [7,8]. 
Despite a tremendous effort over the last two decades to 
establish effective neuroprotective treatments in glaucoma and 
other neuropathies, there are no novel treatments beyond 
those that target lowering the IOP. This approach, 
unfortunately, often turns out to be unsuccessful; thus 
suggesting the involvement of other factors/mechanisms in the 
pathogenesis and/or progression of neurodegenerative 
diseases of the eye [10].  
For nearly 90 years, the ketogenic diet (KD) has been used 
successfully to treat patients with intractable epilepsy. It was 
introduced in clinical use to mimic biochemical changes that 
occur during starvation [11]. The KD is high in fats and low in 
carbohydrates and proteins [12]. During prolonged exposure to 
the KD, energy is mainly derived from the oxidation of fatty 
acids in mitochondria as opposed to glucose being the main 
energy source when exposed to a normal diet. When exposed 
to the KD, fatty acids are oxidised at a high rate, which results 
in an overproduction of acetyl-CoA. The overproduction of 
acetyl-CoA then leads to the synthesis of ketone bodies, such as 
β-hydroxybutyrate, acetoacetate, and acetone, primarily in the 
liver [12]. These ketone bodies serve as energy substrates and 
there is evidence that they can enhance neuronal survival 
under some pathological conditions, including hypoxia, anoxia, 
or ischaemia [13]. It has recently been shown that acetoacetate 
and β-hydroxybutyrate produced a significant dose-dependent 
neuroprotective effect on retinal ganglion cells in a rat model of 
NMDA-induced neuronal damage [14]. The KDs have been 
shown to exert neuroprotective effects in brain trauma [15], 
Alzheimer's disease [16], Parkinson’s disease [17], and 
amyotrophic lateral sclerosis [18]. Also, the anticonvulsant 
effects of KDs have been well documented [19, 20], which is 
consistent with its therapeutic use in the treatment of 
refractory epilepsy [21,22]. 
 
HYPOTHESIS 
It is proposed that the KD may have a therapeutic benefit in 
diseases of the eye associated with neurodegeneration. 
 
DISCUSSION 
When chronically exposed to the KD, the metabolic efficiency of 
the Kreb’s cycle is reduced and the overproduced acetyl-CoA is 
shunted to the production of ketone bodies that are then 
utilised as an energy source in extra-hepatic tissues, including 
the brain. Glucose is normally the sole energy source for the 
human brain, as fatty acids cannot be used because they do not 
cross the blood-brain barrier. Ketone bodies do enter the brain, 
in proportion to the degree of ketosis. Under normal 
conditions, when carbohydrates are abundant, the utilisation of 
ketones by the brain is minimal. When exposed to the KD, 
however, ketone bodies become the major energy source for 
the brain. The ketone bodies are converted to acetyl-CoA by D-
-hydroxybutyrate dehydrogenase, acetoacetate-succinyl-CoA 
transferase and acetoacetyl-CoA-thiolase, and then enter the 
Kreb’s cycle within the mitochondria of the brain to produce 
ATP [12]. 
It has been known since the time of Hippocrates that fasting is 
an effective treatment for seizures, and approaches utilising the 
KD were designed to mimic the fasting state [23]. Despite 
intensive research over recent years, the mechanism by which 
the KD affects seizures remains unknown. The diet is associated 
with a wide range of neurochemical changes, some of which 
may contribute to its therapeutic actions and others that are 
epiphenomena. The current poor understanding of the 
mechanisms involved in the therapeutic effects of the KD is not 
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that different from that for many approved antiepileptic drugs 
(AEDs); levetiracetam can serve as a most recent example. This 
drug was approved many years before its mechanisms of action 
were discovered [24]. 
Although far from definitely proven, there is emerging evidence 
that the KD may also have disease-modifying actions in epilepsy 
and other diseases associated with neuronal death [25]. New 
findings suggest that the KD can be more beneficial for the 
treatment of seizures associated with metabolic stress or 
underlying metabolic abnormalities [26]. 
Much of the neurological dysfunction that occurs in stroke, 
cerebral ischaemia, glaucoma, or acute traumatic brain injury 
patients is due to secondary injury processes involving 
glutamate-mediated excitotoxicity, intracellular calcium 
overload, mitochondrial dysfunction, or the generation of 
reactive oxygen species (ROS) [27]. Consequently, the 
underlying pathophysiological mechanisms may have features 
in common with those in classical neurodegenerative disorders 
(Alzheimer’s and Parkinson’s diseases).  
Mitochondria play important cellular functions that include the 
production of cellular ATP, the control of apoptosis, the 
maintenance of calcium homeostasis, and the production and 
elimination of reactive oxygen species. Chronic exposure to the 
KD stimulates mitochondrial biogenesis, ATP production, and 
phosphocreatine concentrations in the brain, suggesting 
metabolic efficiency [28]. Furthermore, genes encoding 
bioenergetic enzymes are up-regulated by the KD [28, 29]. 
Recently, it was shown that the KD modulates oxidative stress 
and also increases mitochondrial glutathione levels [30,31]. All 
of these findings might be relevant for alleviating a chronic 
neurodegenerative disease, like glaucoma, that clearly exhibits 
features of mitochondrial dysfunction or insufficiency, as well 
as diseases associated with mtDNA depletion, like Leber’s 
hereditary optic neuropathy.  
Recently, Prins and co-workers reported that the KD can confer 
up to a 60% reduction in cortical contusion volume at 7 days 
after controlled cortical injury in rats [32]. Of note, the 
beneficial effects of the KD that was administered after the 
injury only occurred at some postnatal ages, despite the similar 
availability of ketone bodies at all of the studied ages. This led 
the authors to conclude that differences in the ability of the 
brain to utilise ketones at different developmental stages may 
affect the efficacy of ketone bodies-induced protection [33,34]. 
An additional study found that rats receiving the KD were also 
resistant to the loss of cortical neurons during insulin-induced 
hypoglycaemia [35]. Thus, there is evidence that the KD has 
neuroprotective activity in traumatic-, ischaemic-, and 
metabolic-related brain injuries.  
Although the mechanism by which the KD confers protection in 
these diverse injury models is not well understood, ketone 
bodies could play a direct role. For example, β-hydroxybutyrate 
could presumably serve as an alternative energy source to 
mitigate injury-induced ATP depletion. In fact, the exogenous 
administration of β-hydroxybutyrate has been reported to 
reduce brain damage and improve neuronal function in models 
of brain hypoxia, anoxia, and ischaemia [13,36,37,38]. Likewise, 
the other ketone bodies, acetoacetate and acetone, can also 
serve as alternative energy sources and exhibit similar 
neuroprotective effects [39,40,41]. Interestingly, in rats 
maintained on the KD, neuronal uptake of β-hydroxybutyrate 
was increased after cortical impact injury in comparison to 
animals receiving a standard diet [42], suggesting the facilitated 
brain penetrations of ketone bodies when chronically exposed 
to the KD. Moreover, it has been shown that two ketone 
bodies, acetoacetate and β-hydroxybutyrate, can increase the 
formation of brain kynurenic acid that is considered an 
endogenous antagonist of NMDA receptors and a putative 
neuroprotective agent [43,44]. 
The clinical application of the classical KD has been hampered 
by its poor tolerability and potentially serious side-effects. As 
the underlying mechanisms involved in the KD-induced clinical 
benefit become better understood, it could be possible to 
develop alternative therapeutic approaches with similar or 
improved therapeutic effects and reduced liabilities associated 
with chronic exposure to this high-fat diet. Alternative options 
of less restricted diets with presumed improved side-effect 
profiles and/or compliance are being investigated (e.g. the 
Atkins diet, low-glycaemic-index treatment or diets based on 
medium-chain fatty acids) [45]. 
Almost all of the clinical studies on neuroprotection in 
ophthalmologic diseases including glaucoma have so far failed 
to show efficacy, despite encouraging preclinical studies 
[46,47]. Supported by both pre-clinical and clinical evidence 
demonstrating the neuroprotective effects of the KD, it is 
reasonable to consider testing the KD in diseases of the eye 
associated with neurodegeneration. A properly designed 
multicentre study with validated endpoints would yield the 
most useful information in a relatively short time.  
 
CONCLUSION 
There is a paucity of data in the literature on the 
neuroprotective efficacy of the KD and ketone bodies in the 
neurodegeneration of retina and optic nerves. Putative cellular 
mechanisms underlying the neuroprotective activity of the KD 
have been identified in neurological studies focusing, for 
example, on the effects of the KD on energy metabolism, the 
GABA system, glutamate-mediated toxicity, antioxidant 
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mechanisms, programmed cell death, anti-inflammatory 
processes, or the enhancement of kynurenic acid production. 
Importantly, many of these mechanisms have been implicated 
in glaucoma as well. 
When these observations on mechanistic similarities are taken 
together, it raises the possibility that the KD may be 
neuroprotective in certain diseases of the eye such as 
glaucoma, mitochondrial diseases of the optic nerve, or retinal 
ischaemic diseases (diabetic retinopathy and retinopathy of 
prematurity). Proving the efficacy of the KD in these conditions 
would require a proof-of-concept study to be followed, if 
successful, by studies in a larger number of patients. 
 
DISCLOSURE 
The authors report no conflicts of interest in this work. 
 
REFERENCES 
1. Quigley HA. Number of people with glaucoma worldwide. Br J 
Ophthalmol. 1996 May;80(5):389-93. PMID: 8695555. 
2. Gherghel D, Hosking SL, Orgül S. Autonomic nervous system, 
circadian rhythms, and primary open-angle glaucoma. Surv 
Ophthalmol. 2004 Sep-Oct;49(5):491-508. PMID: 15325194. 
3. Nickells RW. Apoptosis of retinal ganglion cells in glaucoma: an 
update of the molecular pathways involved in cell death. Surv 
Ophthalmol. 1999 Jun;43 Suppl 1:S151-61. PMID: 10416758. 
4. Repici M, Mariani J, Borsello T. Neuronal death and 
neuroprotection: a review. Methods Mol Biol. 2007;399:1-14. PMID: 
18309921. 
5. Abu-Amero KK, Morales J, Bosley TM. Mitochondrial abnormalities 
in patients with primary open-angle glaucoma. Invest Ophthalmol Vis 
Sci. 2006 Jun;47(6):2533-41. PMID: 16723467. 
6. Buono LM, Foroozan R, Sergott RC, Savino PJ. Is normal tension 
glaucoma actually an unrecognized hereditary optic neuropathy? 
New evidence from genetic analysis. Curr Opin Ophthalmol. 2002 
Dec;13(6):362-70. PMID: 12441838. 
7. Howell N. LHON and other optic nerve atrophies: the 
mitochondrial connection. Dev Ophthalmol. 2003;37:94-108. PMID: 
12876832. 
8. Bosley TM, Abu-Amero KK, Ozand PT. Mitochondrial DNA 
nucleotide changes in non-arteritic ischemic optic neuropathy. 
Neurology. 2004 Oct 12;63(7):1305-8. PMID: 15477560. 
9. Opial D, Boehnke M, Tadesse S, Lietz-Partzsch A, Flammer J, 
Munier F, Mermoud A, Hirano M, Flückiger F, Mojon DS. Leber's 
hereditary optic neuropathy mitochondrial DNA mutations in normal-
tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 2001 
Jul;239(6):437-40. PMID: 11561792. 
10. Zarnowski T, Kosior-Jarecka E. Progression of normal tension 
glaucoma in Kearns-Sayre syndrome over 10 years. Clin Experiment 
Ophthalmol. 2012 Mar;40(2):218-20. PMID: 22004289. 
11. Wilder RM. The effect of ketonemia on the course of epilepsy. 
Mayo Clin Proc. 1921;2,307-8. 
12. Freeman J, Veggiotti P, Lanzi G, Tagliabue A, Perucca E; Institute 
of Neurology IRCCS C. Mondino Foundation. The ketogenic diet: from 
molecular mechanisms to clinical effects. Epilepsy Res. 2006 
Feb;68(2):145-80. PMID: 16523530. 
13. Suzuki M, Suzuki M, Sato K, Dohi S, Sato T, Matsuura A, Hiraide A. 
Effect of beta-hydroxybutyrate, a cerebral function improving agent, 
on cerebral hypoxia, anoxia and ischemia in mice and rats. Jpn J 
Pharmacol. 2001 Oct;87(2):143-50. PMID: 11700013. 
14. Thaler S, Choragiewicz TJ, Rejdak R, Fiedorowicz M, Turski WA, 
Tulidowicz-Bielak M, Zrenner E, Schuettauf F, Zarnowski T. 
Neuroprotection by acetoacetate and β-hydroxybutyrate against 
NMDA-induced RGC damage in rat--possible involvement of 
kynurenic acid. Graefes Arch Clin Exp Ophthalmol. 2010 
Dec;248(12):1729-35. PMID: 20532550. 
15. Prins ML, Fujima LS, Hovda DA. Age-dependent reduction of 
cortical contusion volume by ketones after traumatic brain injury. J 
Neurosci Res. 2005 Nov 1;82(3):413-20. PMID: 16180224. 
16. Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A 
ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of 
Alzheimer's disease. Nutr Metab (Lond). 2005 Oct 17;2:28. PMID: 
16229744. 
17. Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield 
SB. Treatment of Parkinson disease with diet-induced 
hyperketonemia: a feasibility study. Neurology. 2005 Feb 
22;64(4):728-30. PMID: 15728303. 
18. Zhao Z, Lange DJ, Voustianiouk A, MacGrogan D, Ho L, Suh J, 
Humala N, Thiyagarajan M, Wang J, Pasinetti GM. A ketogenic diet as 
a potential novel therapeutic intervention in amyotrophic lateral 
sclerosis. BMC Neurosci. 2006 Apr 3;7:29. PMID: 16584562. 
 
19. Bough KJ, Eagles DA. A ketogenic diet increases the resistance to 
pentylenetetrazole-induced seizures in the rat. Epilepsia. 1999 
Feb;40(2):138-43. PMID: 9952258. 
20. Appleton DB, DeVivo DC. An animal model for the ketogenic diet. 
Epilepsia. 1974 Jun;15(2):211-27. PMID: 4525180. 
21. Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly LM. The 
efficacy of the ketogenic diet-1998: a prospective evaluation of 
intervention in 150 children. Pediatrics. 1998 Dec;102(6):1358-63. 
PMID: 9832569. 
22. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, 
Fitzsimmons G, Whitney A, Cross JH. The ketogenic diet for the 
treatment of childhood epilepsy: a randomised controlled trial. 
Lancet Neurol. 2008 Jun;7(6):500-6. PMID: 18456557. 
23. Bailey EE, Pfeifer HH, Thiele EA. The use of diet in the treatment 
of epilepsy. Epilepsy Behav. 2005 Feb;6(1):4-8. PMID: 15652725. 
24. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, 
Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding 
site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 
2004 Jun 29;101(26):9861-6. PMID: 15210974. 
25. Gasior M, Rogawski MA, Hartman AL. Neuroprotective and 
disease-modifying effects of the ketogenic diet. Behav Pharmacol. 
2006 Sep;17(5-6):431-9. PMID: 16940764. 
26. Samoilova M, Weisspapir M, Abdelmalik P, Velumian AA, Carlen 
PL. Chronic in vitro ketosis is neuroprotective but not anti-convulsant. 
J Neurochem. 2010 May;113(4):826-35. PMID: 20163521. 
27. McIntosh TK, Saatman KE, Raghupathi R, Graham DI, Smith DH, 
Lee VM, Trojanowski JQ. The Dorothy Russell Memorial Lecture. The 
molecular and cellular sequelae of experimental traumatic brain 
 
 
MEHDI Ophthalmology Journal 2012; Vol. 1, No 3  
 
49 A KETOGENIC DIET MAY OFFER NEUROPROTECTION IN GLAUCOMA AND MITOCHONDRIAL DISEASES 
injury: pathogenetic mechanisms. Neuropathol Appl Neurobiol. 1998 
Aug;24(4):251-67. PMID: 9775390. 
28. Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene 
JG, Shaw R, Smith Y, Geiger JD, Dingledine RJ. Mitochondrial 
biogenesis in the anticonvulsant mechanism of the ketogenic diet. 
Ann Neurol. 2006 Aug;60(2):223-35. PMID: 16807920. 
29. Noh HS, Kang SS, Kim DW, Kim YH, Park CH, Han JY, Cho GJ, Choi 
WS. Ketogenic diet increases calbindin-D28k in the hippocampi of 
male ICR mice with kainic acid seizures. Epilepsy Res. 2005 
Jul;65(3):153-9. PMID: 16046100. 
30. Milder J, Patel M. Modulation of oxidative stress and 
mitochondrial function by the ketogenic diet. Epilepsy Res. 2012 
Jul;100(3):295-303. PMID: 22078747. 
31. Jarrett SG, Milder JB, Liang LP, Patel M. The ketogenic diet 
increases mitochondrial glutathione levels. J Neurochem. 2008 
Aug;106(3):1044-51. PMID: 18466343. 
32. Prins ML, Fujima LS, Hovda DA. Age-dependent reduction of 
cortical contusion volume by ketones after traumatic brain injury. J 
Neurosci Res. 2005 Nov 1;82(3):413-20. PMID: 16180224. 
33. Rafiki A, Boulland JL, Halestrap AP, Ottersen OP, Bergersen L. 
Highly differential expression of the monocarboxylate transporters 
MCT2 and MCT4 in the developing rat brain. Neuroscience. 
2003;122(3):677-88. PMID: 14622911. 
34. Vannucci SJ, Simpson IA. Developmental switch in brain nutrient 
transporter expression in the rat. Am J Physiol Endocrinol Metab. 
2003 Nov;285(5):E1127-34. PMID: 14534079. 
35. Yamada KA, Rensing N, Thio LL. Ketogenic diet reduces 
hypoglycemia-induced neuronal death in young rats. Neurosci Lett. 
2005 Sep 16;385(3):210-4. PMID: 15975714. 
36. Cherian L, Peek K, Robertson CS, Goodman JC, Grossman RG. 
Calorie sources and recovery from central nervous system ischemia. 
Crit Care Med. 1994 Nov;22(11):1841-50. PMID: 7956290. 
37. Dardzinski BJ, Smith SL, Towfighi J, Williams GD, Vannucci RC, 
Smith MB. Increased plasma beta-hydroxybutyrate, preserved 
cerebral energy metabolism, and amelioration of brain damage 
during neonatal hypoxia ischemia with dexamethasone 
pretreatment. Pediatr Res. 2000 Aug;48(2):248-55. PMID: 10926303. 
38. Suzuki M, Suzuki M, Kitamura Y, Mori S, Sato K, Dohi S, Sato T, 
Matsuura A, Hiraide A. Beta-hydroxybutyrate, a cerebral function 
improving agent, protects rat brain against ischemic damage caused 
by permanent and transient focal cerebral ischemia. Jpn J Pharmacol. 
2002 May;89(1):36-43. PMID: 12083741. 
39. Massieu L, Del Río P, Montiel T. Neurotoxicity of glutamate 
uptake inhibition in vivo: correlation with succinate dehydrogenase 
activity and prevention by energy substrates. Neuroscience. 
2001;106(4):669-77. PMID: 11682154. 
40. Massieu L, Haces ML, Montiel T, Hernández-Fonseca K. 
Acetoacetate protects hippocampal neurons against glutamate-
mediated neuronal damage during glycolysis inhibition. 
Neuroscience. 2003;120(2):365-78. PMID: 12890508. 
41. Noh HS, Hah YS, Nilufar R, Han J, Bong JH, Kang SS, Cho GJ, Choi 
WS. Acetoacetate protects neuronal cells from oxidative glutamate 
toxicity. J Neurosci Res. 2006 Mar;83(4):702-9. PMID: 16435389. 
42. Prins ML, Lee SM, Fujima LS, Hovda DA. Increased cerebral uptake 
and oxidation of exogenous betaHB improves ATP following 
traumatic brain injury in adult rats. J Neurochem. 2004 
Aug;90(3):666-72. PMID: 15255945. 
43. Hodgkins PS, Schwarcz R. Interference with cellular energy 
metabolism reduces kynurenic acid formation in rat brain slices: 
reversal by lactate and pyruvate. Eur J Neurosci. 1998 Jun;10(6):1986-
94. PMID: 9753086. 
44. Hodgkins PS, Schwarcz R. Metabolic control of kynurenic acid 
formation in the rat brain. Dev Neurosci. 1998;20(4-5):408-16. PMID: 
9778579. 
45. Kessler SK, Neal EG, Camfield CS, Kossoff EH. Dietary therapies for 
epilepsy: future research. Epilepsy Behav. 2011 Sep;22(1):17-22. 
PMID: 21441072. 
46. Danesh-Meyer HV, Levin LA. Neuroprotection: extrapolating from 
neurologic diseases to the eye. Am J Ophthalmol. 2009 
Aug;148(2):186-191.e2. PMID: 19464671. 
47. Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment 
of glaucoma in adults. Cochrane Database Syst Rev. 2010 Feb 
17;(2):CD006539. PMID: 20166085. 
 
